Dialysate Concentrates Used in Hemodialysis: Safety Communication - Alkali Dosing Errors
MedSun: Newsletter #73, June 2012

FDA MedWatch Safety Alert

Health care providers should review the dialysate acid concentrate labeling for the specific concentrate that they prescribe to determine the components that can contribute to the patient's overall bicarbonate levels. Be aware that metabolic alkalosis (pre-dialysis serum bicarbonate levels > or = to 27 mEq/L) has been associated with a higher risk of death in hemodialysis patients.

Additional Information:

FDA MedWatch Safety Alert. Dialysate Concentrates Used in Hemodialysis: Safety Communication - Alkali Dosing Errors. May 25, 2012.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm305630.htm


MedSun Newsletters are available at www.fda.gov/cdrh/medsun